Segmented Plasminogen Peptides for Angiogenesis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating angiogenesis, particularly in treating diseases related to inadequate or excessive blood vessel formation, have shown limited efficacy and safety, with existing angiogenesis inhibitors and stimulators failing to provide consistent results in clinical applications.
Innovation Solution
Development of novel synthetic lytic peptide fragments, such as FAKKFAKKFK, IVRRADRAAVPIVNLKDELL, and MFGNGKGYRGKRATTVTGTP, which can inhibit or stimulate angiogenesis, offering potential therapeutic agents for treating various disorders by administering these peptide fragments to modulate angiogenic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional angiogenesis inhibitors or stimulators are used, then angiogenic activity is modulated, but therapeutic efficacy and safety are limited
Solution Approach 1:
The patent segments the full-length plasminogen molecule into smaller functional peptide fragments (such as the C1 fragment comprising amino acids 554-572). This segmentation allows isolation of specific angiogenic or anti-angiogenic domains while removing potentially harmful or inactive portions, thereby improving therapeutic efficacy and safety profile compared to using the complete molecule or non-specific agents.
Solution Approach 2:
The patent modifies molecular parameters by creating synthetic peptide fragments with specific amino acid sequences derived from plasminogen. By changing the molecular size, sequence composition, and structural characteristics from the full-length protein to targeted fragments, the invention achieves enhanced specificity and reduced side effects while maintaining or improving angiogenic modulation efficacy.
2Reliability
If existing angiogenesis therapies are applied, then blood vessel formation is modulated, but consistent clinical results are not achieved
Solution Approach 1:
The patent applies local quality by targeting specific functional domains within the plasminogen molecule (such as the C1 fragment with specific amino acid sequence) that are responsible for angiogenic activity. This localized approach ensures consistent interaction with endothelial cells and vascular factors, producing reliable clinical results by focusing therapeutic action on the precise molecular region that mediates the desired effect.
Data Source
AI summary
This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity.